v. 28 – Q4 2023

Market Executive Summary Lebanon is implementing Trace and Trace Serialisation to align with the Emerging Global Standard (EGS). This implementation is being done to enable traceability of pharmaceutical products in the supply chain to increase patient safety and prevent counterfeiting. This has been mandated by the Ministry of Public Health.

The scope of this implementation will include all pharmaceutical products imported, manufactured and sold in Lebanon excluding free medical samples and IV fluids. As of Q2 2020, labelling requirements have been released and are documented below. The database to upload and retain product information and transaction data, MediTrack, has been introduced and is required to be used by importers, manufacturers and distributors.

Key Dates
  • July 2022: MoH released on 13 July 2022, Decision No. 647/1 regarding medicinal traceability – this follows 2017 Decree requiring all imported drugs to have 2D DM and Lebanese manufacturers to apply 2D DM starting 1 January 2023.
  • April 2022: Roll-out of the MediTrack platform is starting up, initially with focus on cancer and chronic illness drugs at hospitals.
  • April 2021:
    • Importers, manufacturers, and distributors are required to upload required data to Meditrack Database
    • 2D DM with Batch Variable coding required (original date 1-July-2018) for locally manufactured medicines
  • January 2020: Expected aggregation and reporting requirements but not yet announced
  • December 2019: 2D DM with Batch Variable coding required (original date 1-July-2018) for imported medicines
  • January 2019: From this date, any pharmaceutical product that does not hold the 2D Matrix Barcode is not allowed to be imported

<-- Return to Countries